AU2016363113A1 - Monitoring treatment or progression of myeloma - Google Patents
Monitoring treatment or progression of myeloma Download PDFInfo
- Publication number
- AU2016363113A1 AU2016363113A1 AU2016363113A AU2016363113A AU2016363113A1 AU 2016363113 A1 AU2016363113 A1 AU 2016363113A1 AU 2016363113 A AU2016363113 A AU 2016363113A AU 2016363113 A AU2016363113 A AU 2016363113A AU 2016363113 A1 AU2016363113 A1 AU 2016363113A1
- Authority
- AU
- Australia
- Prior art keywords
- kras
- nras
- individual
- cell
- nucleic acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010035226 Plasma cell myeloma Diseases 0.000 title claims abstract description 221
- 238000011282 treatment Methods 0.000 title claims abstract description 160
- 238000012544 monitoring process Methods 0.000 title claims abstract description 37
- 201000000050 myeloid neoplasm Diseases 0.000 title abstract description 78
- 230000035772 mutation Effects 0.000 claims abstract description 288
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 201
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 197
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 197
- 208000034578 Multiple myelomas Diseases 0.000 claims abstract description 143
- 102100030708 GTPase KRas Human genes 0.000 claims abstract description 133
- 238000000034 method Methods 0.000 claims abstract description 131
- 102100039788 GTPase NRas Human genes 0.000 claims abstract description 104
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims abstract description 81
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 78
- 239000011886 peripheral blood Substances 0.000 claims abstract description 78
- 101150080074 TP53 gene Proteins 0.000 claims abstract description 58
- 108700025694 p53 Genes Proteins 0.000 claims abstract description 58
- 101150105104 Kras gene Proteins 0.000 claims abstract description 56
- 101150073096 NRAS gene Proteins 0.000 claims abstract description 56
- 101150048834 braF gene Proteins 0.000 claims abstract description 55
- 230000004044 response Effects 0.000 claims abstract description 52
- 239000002773 nucleotide Substances 0.000 claims abstract description 49
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 49
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 25
- 230000009467 reduction Effects 0.000 claims abstract description 9
- 210000001185 bone marrow Anatomy 0.000 claims description 105
- 108020004414 DNA Proteins 0.000 claims description 83
- 238000012360 testing method Methods 0.000 claims description 82
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims description 77
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 72
- 201000010099 disease Diseases 0.000 claims description 69
- 206010028980 Neoplasm Diseases 0.000 claims description 63
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 50
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 42
- 229940079593 drug Drugs 0.000 claims description 42
- 239000003814 drug Substances 0.000 claims description 42
- 229960003957 dexamethasone Drugs 0.000 claims description 41
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 36
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 35
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 32
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 32
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 32
- 238000001514 detection method Methods 0.000 claims description 28
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 26
- 238000003745 diagnosis Methods 0.000 claims description 24
- 229960004397 cyclophosphamide Drugs 0.000 claims description 23
- 102200006539 rs121913529 Human genes 0.000 claims description 23
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 22
- 210000005087 mononuclear cell Anatomy 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 102200006531 rs121913529 Human genes 0.000 claims description 22
- 230000037361 pathway Effects 0.000 claims description 21
- 102200006537 rs121913529 Human genes 0.000 claims description 16
- 102200104041 rs28934576 Human genes 0.000 claims description 16
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 15
- 229960004316 cisplatin Drugs 0.000 claims description 15
- 102200124923 rs121913254 Human genes 0.000 claims description 15
- 102000016914 ras Proteins Human genes 0.000 claims description 13
- 102200006532 rs112445441 Human genes 0.000 claims description 13
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 12
- 229940126685 KRAS G12R Drugs 0.000 claims description 12
- 229960002756 azacitidine Drugs 0.000 claims description 12
- 102200124917 rs121434595 Human genes 0.000 claims description 12
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 11
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 11
- 229960003433 thalidomide Drugs 0.000 claims description 11
- 229960001467 bortezomib Drugs 0.000 claims description 10
- 102200055464 rs113488022 Human genes 0.000 claims description 10
- 102200124916 rs121434596 Human genes 0.000 claims description 10
- 102200006541 rs121913530 Human genes 0.000 claims description 10
- 102220014328 rs121913535 Human genes 0.000 claims description 9
- -1 Vemurafinib Chemical compound 0.000 claims description 8
- 229960005184 panobinostat Drugs 0.000 claims description 8
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims description 8
- 102200006540 rs121913530 Human genes 0.000 claims description 8
- 229960003648 ixazomib Drugs 0.000 claims description 7
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 claims description 7
- 229950006764 rigosertib Drugs 0.000 claims description 7
- OWBFCJROIKNMGD-BQYQJAHWSA-N rigosertib Chemical compound COC1=CC(OC)=CC(OC)=C1\C=C\S(=O)(=O)CC1=CC=C(OC)C(NCC(O)=O)=C1 OWBFCJROIKNMGD-BQYQJAHWSA-N 0.000 claims description 7
- 102200104161 rs121912651 Human genes 0.000 claims description 7
- 102200006538 rs121913530 Human genes 0.000 claims description 7
- 229960004066 trametinib Drugs 0.000 claims description 7
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims description 7
- 238000009826 distribution Methods 0.000 claims description 6
- 229950009791 durvalumab Drugs 0.000 claims description 5
- 229960002621 pembrolizumab Drugs 0.000 claims description 5
- 210000000130 stem cell Anatomy 0.000 claims description 5
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 4
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 4
- 102000043136 MAP kinase family Human genes 0.000 claims description 4
- 108091054455 MAP kinase family Proteins 0.000 claims description 4
- 229960002271 cobimetinib Drugs 0.000 claims description 4
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 claims description 4
- 102220197775 rs1057519695 Human genes 0.000 claims description 4
- 102200124919 rs121913237 Human genes 0.000 claims description 4
- 102220195076 rs121913255 Human genes 0.000 claims description 4
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 claims description 4
- 229950010746 selumetinib Drugs 0.000 claims description 4
- 229960003787 sorafenib Drugs 0.000 claims description 4
- 230000001502 supplementing effect Effects 0.000 claims description 3
- 108010010285 Forkhead Box Protein L2 Proteins 0.000 claims description 2
- 102100035137 Forkhead box protein L2 Human genes 0.000 claims description 2
- 102100032610 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Human genes 0.000 claims description 2
- 101001014590 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Proteins 0.000 claims description 2
- 101001014594 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms short Proteins 0.000 claims description 2
- 101001014610 Homo sapiens Neuroendocrine secretory protein 55 Proteins 0.000 claims description 2
- 101000797903 Homo sapiens Protein ALEX Proteins 0.000 claims description 2
- 102200106274 rs121912656 Human genes 0.000 claims description 2
- 229960003862 vemurafenib Drugs 0.000 claims description 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 2
- 102220057256 rs730881168 Human genes 0.000 claims 8
- 102200006520 rs121913240 Human genes 0.000 claims 7
- 102200124924 rs11554290 Human genes 0.000 claims 4
- 102200104154 rs28934571 Human genes 0.000 claims 4
- 102200106275 rs28934575 Human genes 0.000 claims 3
- 101000637010 Physarum polycephalum Terpene synthase 3 Proteins 0.000 claims 2
- 102200103765 rs121913343 Human genes 0.000 claims 2
- 102200055461 rs121913366 Human genes 0.000 claims 2
- 102200007373 rs17851045 Human genes 0.000 claims 2
- 235000003625 Acrocomia mexicana Nutrition 0.000 claims 1
- 244000202285 Acrocomia mexicana Species 0.000 claims 1
- 108700002808 N-Me-Phe(3)- morphiceptin Proteins 0.000 claims 1
- 229910002794 Si K Inorganic materials 0.000 claims 1
- 102220477109 Zinc finger CW-type PWWP domain protein 2_W30R_mutation Human genes 0.000 claims 1
- 239000003596 drug target Substances 0.000 claims 1
- 102220197830 rs1057519725 Human genes 0.000 claims 1
- 102220014333 rs112445441 Human genes 0.000 claims 1
- 102200104166 rs11540652 Human genes 0.000 claims 1
- 102220197780 rs121434596 Human genes 0.000 claims 1
- 102200108472 rs121912654 Human genes 0.000 claims 1
- 102220011004 rs121913237 Human genes 0.000 claims 1
- 102220050982 rs121913250 Human genes 0.000 claims 1
- 102200085788 rs121913279 Human genes 0.000 claims 1
- 102200085789 rs121913279 Human genes 0.000 claims 1
- 102200044897 rs121913407 Human genes 0.000 claims 1
- 102200044886 rs121913409 Human genes 0.000 claims 1
- 102200007377 rs121913527 Human genes 0.000 claims 1
- 102200114273 rs199714731 Human genes 0.000 claims 1
- 102200104847 rs28934574 Human genes 0.000 claims 1
- 102200102887 rs28934578 Human genes 0.000 claims 1
- 206010061818 Disease progression Diseases 0.000 abstract description 17
- 230000005750 disease progression Effects 0.000 abstract description 17
- 239000000523 sample Substances 0.000 description 144
- 210000002381 plasma Anatomy 0.000 description 96
- 239000013615 primer Substances 0.000 description 43
- 238000003752 polymerase chain reaction Methods 0.000 description 38
- 230000000869 mutational effect Effects 0.000 description 28
- 238000011304 droplet digital PCR Methods 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 22
- 238000002560 therapeutic procedure Methods 0.000 description 20
- 230000000295 complement effect Effects 0.000 description 19
- 238000012163 sequencing technique Methods 0.000 description 19
- 238000001574 biopsy Methods 0.000 description 17
- 230000003321 amplification Effects 0.000 description 15
- 238000013459 approach Methods 0.000 description 15
- 238000003199 nucleic acid amplification method Methods 0.000 description 15
- 238000003753 real-time PCR Methods 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 12
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 12
- 108091093088 Amplicon Proteins 0.000 description 11
- 230000003213 activating effect Effects 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 10
- 229960005420 etoposide Drugs 0.000 description 10
- 102000015094 Paraproteins Human genes 0.000 description 9
- 108010064255 Paraproteins Proteins 0.000 description 9
- 239000011324 bead Substances 0.000 description 9
- 238000012512 characterization method Methods 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 229940120975 revlimid Drugs 0.000 description 8
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 7
- 102100035721 Syndecan-1 Human genes 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000011269 treatment regimen Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 206010069755 K-ras gene mutation Diseases 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229960004942 lenalidomide Drugs 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000003908 quality control method Methods 0.000 description 4
- 239000002096 quantum dot Substances 0.000 description 4
- 230000000153 supplemental effect Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- 238000007482 whole exome sequencing Methods 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 102100027211 Albumin Human genes 0.000 description 3
- 102100036030 Conserved oligomeric Golgi complex subunit 5 Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101000876001 Homo sapiens Conserved oligomeric Golgi complex subunit 5 Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000001254 nonsecretory effect Effects 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 208000037922 refractory disease Diseases 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000000405 serological effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 208000007452 Plasmacytoma Diseases 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- 108091092240 circulating cell-free DNA Proteins 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 238000004802 monitoring treatment efficacy Methods 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 208000037821 progressive disease Diseases 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000013515 script Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 238000012070 whole genome sequencing analysis Methods 0.000 description 2
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102100028914 Catenin beta-1 Human genes 0.000 description 1
- 101710150820 Cellular tumor antigen p53 Proteins 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000006311 Cyclin D1 Human genes 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102100037859 G1/S-specific cyclin-D3 Human genes 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 102100029234 Histone-lysine N-methyltransferase NSD2 Human genes 0.000 description 1
- 101710196680 Histone-lysine N-methyltransferase NSD2 Proteins 0.000 description 1
- 101100381977 Homo sapiens BRAF gene Proteins 0.000 description 1
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 description 1
- 101000738559 Homo sapiens G1/S-specific cyclin-D3 Proteins 0.000 description 1
- 101100086477 Homo sapiens KRAS gene Proteins 0.000 description 1
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 1
- 101000630267 Homo sapiens Probable glutamate-tRNA ligase, mitochondrial Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000962461 Homo sapiens Transcription factor Maf Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 101150039798 MYC gene Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102100030569 Nuclear receptor corepressor 2 Human genes 0.000 description 1
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 101100135116 Oryza sativa subsp. japonica RR12 gene Proteins 0.000 description 1
- 101100135117 Oryza sativa subsp. japonica RR13 gene Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 1
- 102100026125 Probable glutamate-tRNA ligase, mitochondrial Human genes 0.000 description 1
- 241001296096 Probles Species 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101150116266 RR24 gene Proteins 0.000 description 1
- 101000613608 Rattus norvegicus Monocyte to macrophage differentiation factor Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 101710183263 Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 238000003646 Spearman's rank correlation coefficient Methods 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102100039189 Transcription factor Maf Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 201000009200 autoimmune lymphoproliferative syndrome type 4 Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 108091092259 cell-free RNA Proteins 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000006569 extramedullary plasmacytoma Diseases 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 102000050152 human BRAF Human genes 0.000 description 1
- 102000049555 human KRAS Human genes 0.000 description 1
- 102000047526 human NRAS Human genes 0.000 description 1
- 102000048958 human TP53 Human genes 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005746 immune checkpoint blockade Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000015266 indolent plasma cell myeloma Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000009092 lines of therapy Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019689 luncheon sausage Nutrition 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 102200114508 rs201382018 Human genes 0.000 description 1
- 102220073986 rs796052042 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015905013A AU2015905013A0 (en) | 2015-12-03 | Monitoring treatment or progression of myeloma | |
| AU2015905013 | 2015-12-03 | ||
| AU2016903019A AU2016903019A0 (en) | 2016-08-01 | Monitoring treatment or progression of myeloma (2) | |
| AU2016903019 | 2016-08-01 | ||
| PCT/AU2016/051191 WO2017091865A1 (en) | 2015-12-03 | 2016-12-02 | Monitoring treatment or progression of myeloma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2016363113A1 true AU2016363113A1 (en) | 2018-06-07 |
Family
ID=58796005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016363113A Abandoned AU2016363113A1 (en) | 2015-12-03 | 2016-12-02 | Monitoring treatment or progression of myeloma |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20180282820A1 (https=) |
| EP (1) | EP3384050A4 (https=) |
| JP (2) | JP2018537128A (https=) |
| KR (1) | KR20180088690A (https=) |
| CN (1) | CN108603232A (https=) |
| AU (1) | AU2016363113A1 (https=) |
| CA (1) | CA3007426A1 (https=) |
| WO (1) | WO2017091865A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11111543B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| US9424392B2 (en) | 2005-11-26 | 2016-08-23 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
| US9677118B2 (en) | 2014-04-21 | 2017-06-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US20190010543A1 (en) | 2010-05-18 | 2019-01-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12221653B2 (en) | 2010-05-18 | 2025-02-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12152275B2 (en) | 2010-05-18 | 2024-11-26 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| AU2011358564B9 (en) | 2011-02-09 | 2017-07-13 | Natera, Inc | Methods for non-invasive prenatal ploidy calling |
| US20140100126A1 (en) | 2012-08-17 | 2014-04-10 | Natera, Inc. | Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data |
| US20180173845A1 (en) | 2014-06-05 | 2018-06-21 | Natera, Inc. | Systems and Methods for Detection of Aneuploidy |
| WO2016183106A1 (en) | 2015-05-11 | 2016-11-17 | Natera, Inc. | Methods and compositions for determining ploidy |
| WO2017181202A2 (en) | 2016-04-15 | 2017-10-19 | Natera, Inc. | Methods for lung cancer detection |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| GB201618485D0 (en) | 2016-11-02 | 2016-12-14 | Ucl Business Plc | Method of detecting tumour recurrence |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| AU2018288832B2 (en) | 2017-06-20 | 2025-03-06 | The Medical College Of Wisconsin, Inc. | Assessing transplant complication risk with total cell-free DNA |
| WO2019075251A2 (en) * | 2017-10-12 | 2019-04-18 | Nantomics, Llc | CANCER SCORE FOR EVALUATION AND PREDICTION OF RESPONSE FROM BIOLOGICAL FLUIDS |
| CN107881233A (zh) * | 2017-10-31 | 2018-04-06 | 天津协和华美医学诊断技术有限公司 | 一种检测骨髓瘤相关基因群的检测试剂盒 |
| JP2021506342A (ja) | 2017-12-14 | 2021-02-22 | ティーエーアイ ダイアグノスティックス インコーポレイテッドＴａｉ Ｄｉａｇｎｏｓｔｉｃｓ，Ｉｎｃ． | 移植のための移植片適合性の評価 |
| CA3090426A1 (en) | 2018-04-14 | 2019-10-17 | Natera, Inc. | Methods for cancer detection and monitoring by means of personalized detection of circulating tumor dna |
| WO2019207439A1 (en) * | 2018-04-23 | 2019-10-31 | Inivata Ltd. | Method for predicting and monitoring response to an immune checkpoint inhibitor |
| US12234509B2 (en) | 2018-07-03 | 2025-02-25 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
| JP7407193B2 (ja) | 2018-08-08 | 2023-12-28 | イニヴァータ リミテッド | 可変の複製多重ｐｃｒを使用した配列決定方法 |
| EP3874042A4 (en) * | 2018-10-29 | 2023-06-28 | Molecular Stethoscope, Inc. | Characterization of bone marrow using cell-free messenger-rna |
| CA3117675A1 (en) * | 2018-10-30 | 2020-05-07 | Molecular Stethoscope, Inc. | Cell-free rna library preparations |
| EP3899033A4 (en) * | 2018-12-17 | 2022-10-19 | The Medical College of Wisconsin, Inc. | Assessing risk with total cell-free dna |
| US11931674B2 (en) | 2019-04-04 | 2024-03-19 | Natera, Inc. | Materials and methods for processing blood samples |
| US20210087638A1 (en) * | 2019-09-23 | 2021-03-25 | Dana-Farber Cancer Institute, Inc. | Next-generation sequencing assay for genomic characterization and minimal residual disease detection in the bone marrow, peripheral blood, and urine of multiple myeloma and smoldering myeloma patients |
| CN112760290A (zh) * | 2019-10-21 | 2021-05-07 | 郑州大学 | 携带突变的肿瘤驱动基因的干细胞及其用途 |
| WO2021092476A1 (en) * | 2019-11-06 | 2021-05-14 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and systems for analyzing nucleic acid molecules |
| FR3105738B1 (fr) * | 2019-12-26 | 2024-01-05 | P M B | Dispositif d’irradiation collaboratif |
| CN112698037B (zh) * | 2021-03-25 | 2021-06-25 | 北京积水潭医院 | 一种检测多发性骨髓瘤治疗效果的抗体组合物及其试剂盒和应用 |
| CN116679065B (zh) * | 2023-07-31 | 2023-11-14 | 北京大学人民医院 | 检测试剂的应用、多发性骨髓瘤治疗预后预测方法及产品 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110152357A1 (en) * | 2008-08-12 | 2011-06-23 | The Ohio State University | Micro-RNA-Based Compositions and Methods for the Diagnosis, Prognosis and Treatment of Multiple Myeloma |
| CA2779843A1 (en) * | 2009-11-13 | 2011-05-19 | Infinity Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| CA2855368A1 (en) * | 2011-11-11 | 2013-05-16 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
| CN113337604A (zh) * | 2013-03-15 | 2021-09-03 | 莱兰斯坦福初级大学评议会 | 循环核酸肿瘤标志物的鉴别和用途 |
| AU2014336987A1 (en) * | 2013-10-19 | 2016-04-14 | Trovagene, Inc. | Detecting mutations in disease over time |
-
2016
- 2016-12-02 EP EP16869417.2A patent/EP3384050A4/en not_active Withdrawn
- 2016-12-02 AU AU2016363113A patent/AU2016363113A1/en not_active Abandoned
- 2016-12-02 CA CA3007426A patent/CA3007426A1/en active Pending
- 2016-12-02 WO PCT/AU2016/051191 patent/WO2017091865A1/en not_active Ceased
- 2016-12-02 KR KR1020187018220A patent/KR20180088690A/ko not_active Withdrawn
- 2016-12-02 US US15/776,770 patent/US20180282820A1/en not_active Abandoned
- 2016-12-02 JP JP2018548246A patent/JP2018537128A/ja active Pending
- 2016-12-02 CN CN201680070973.XA patent/CN108603232A/zh active Pending
-
2021
- 2021-10-07 JP JP2021165655A patent/JP2022000059A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022000059A (ja) | 2022-01-04 |
| US20180282820A1 (en) | 2018-10-04 |
| EP3384050A1 (en) | 2018-10-10 |
| CN108603232A (zh) | 2018-09-28 |
| EP3384050A4 (en) | 2019-07-31 |
| WO2017091865A1 (en) | 2017-06-08 |
| CA3007426A1 (en) | 2017-06-08 |
| JP2018537128A (ja) | 2018-12-20 |
| KR20180088690A (ko) | 2018-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20180282820A1 (en) | Monitoring treatment or progression of myeloma | |
| US12139763B2 (en) | Methods for subtyping of lung adenocarcinoma | |
| US11111541B2 (en) | Diagnostic MiRNA markers for Parkinson's disease | |
| US10457988B2 (en) | MiRNAs as diagnostic markers | |
| CN104981548A (zh) | 用于阿尔茨海默氏病的诊断性miRNA标志物 | |
| AU2021291586A1 (en) | Multimodal analysis of circulating tumor nucleic acid molecules | |
| US20170130269A1 (en) | Diagnosis of neuromyelitis optica vs. multiple sclerosis using mirna biomarkers | |
| CN110741096A (zh) | 用于检测循环肿瘤dna的组合物和方法 | |
| WO2017112738A1 (en) | Methods for measuring microsatellite instability | |
| KR101828125B1 (ko) | 다발성 경화증에서의 진단 miRNA 프로파일 | |
| EP3775274B1 (en) | Detection method of somatic genetic anomalies, combination of capture probes and kit of detection | |
| JP2021505143A (ja) | 多血小板血漿サンプルからの核酸の検出 | |
| EP4399329A1 (en) | Method of detecting and quantifying genomic and gene expression alterations using rna | |
| KR102156699B1 (ko) | 소음인 판별용 조성물 | |
| JP2026505350A (ja) | 尿中の腎同種移植片拒絶反応遺伝子を同定するための方法およびそれらの測定を行うことの有用性 | |
| Tsui et al. | Applications of circulating DNA analysis in personalized medicine | |
| CN118139987A (zh) | 用于cfrna和cftna靶向ngs测序的组合物和方法 | |
| EP3696283B1 (en) | Molecular markers in bladder cancer | |
| BR122020011728B1 (pt) | Método para detectar pelo menos uma mutação em uma pluralidade de genes relacionados a câncer de tireoide, para selecionar um sujeito que tem nódulos na tireoide com citologia indeterminada para cirurgia diagnóstica, e para prognosticar risco de malignidade em um sujeito com resultados de citologia para paaf da tireoide inconclusivos, e, kit para detectar pelo menos uma mutação em genes relacionados ao câncer de tireoide em uma amostra ffpe da tireoide ou uma amostra paaf da tireoide, e para detectar pelo menos um produto de fusão genética em uma amostra ffpe da tireoide ou uma amostra paaf da tireoide | |
| BR112018013430B1 (pt) | Métodos para detectar pelo menos uma mutação em uma pluralidade de genes relacionados a câncer de tireoide, para selecionar um sujeito que tem nódulos na tireoide, e, para prognosticar risco de malignidade |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |